In 119 patients with cisplatin-eligible muscle-invasive bladder cancer, neoadjuvant ddMVAC plus durvalumab had a posterior mean pCR of 48.7% vs 46.3% with added tremelimumab (noncomparative phase II); grade ≥3 treatment-related AEs were 30.5% vs 49.6%.
RCTn = 119
Thibault et al. Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study